{"nctId":"NCT01722604","briefTitle":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","startDateStruct":{"date":"2012-01"},"conditions":["Glaucoma","Open Angle or Ocular Hypertension"],"count":258,"armGroups":[{"label":"Azopt 1% ophthalmic suspension","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Azopt 1%"]},{"label":"Brinzolamide 1% ophthalmic suspension","type":"EXPERIMENTAL","interventionNames":["Drug: brinzolamide 1% ophthalmic suspension"]}],"interventions":[{"name":"brinzolamide 1% ophthalmic suspension","otherNames":[]},{"name":"Azopt 1%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and females 18 years of age or older,\n* diagnosed with primary open-angle glaucoma or ocular hypertension.\n\nExclusion Criteria:\n\n* Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle glaucoma,\n* ocular hypertension.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intraocular Pressure (IOP) at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":"3.21"},{"groupId":"OG001","value":"20.8","spread":"3.37"}]}]}]},{"type":"SECONDARY","title":"Change in Intraocular Pressure (IOP) From Baseline to Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"2.79"},{"groupId":"OG001","value":"-5.4","spread":"3.27"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":129},"commonTop":["Instillation site complication"]}}}